Systemic cancer immunotherapy with Toll-like receptor 7 agonists: Timing is everything
Toll-like receptor (TLR) 7 agonists represent a promising strategy for the immunotherapy of cancer. We have recently investigated the influence of TLR tolerance on the efficacy of systemic tumor treatment with TLR7 ligands. We propose that considering the kinetics of receptor sensitivity highly impr...
| Main Authors: | , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Landes Bioscience
2012
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3376978/ |